Christopher Marai
Stock Analyst at Nomura
(2.44)
# 2,404
Out of 5,163 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $9.41 | +10,101.91% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $92.36 | -64.27% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $7.31 | +1,131.19% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $313.41 | -76.39% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $4.46 | +259.15% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $181.55 | +115.92% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.69 | +1,911.83% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $16.40 | +1,302.44% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $23.50 | -48.94% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $9.21 | +106.30% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $3.42 | +1,157.31% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $9.41
Upside: +10,101.91%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $92.36
Upside: -64.27%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $7.31
Upside: +1,131.19%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $313.41
Upside: -76.39%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $4.46
Upside: +259.15%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $181.55
Upside: +115.92%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.69
Upside: +1,911.83%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $16.40
Upside: +1,302.44%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $23.50
Upside: -48.94%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $9.21
Upside: +106.30%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $3.42
Upside: +1,157.31%